Shares of Mecure Industries Plc have staged a dramatic rally on the Nigerian Exchange (NGX), surging 98.56 percent month-to-date in mid-December and decisively breaking above the ₦50 psychological price level. The stock, which is now trading at ₦55.00, has emerged as one of the strongest performers on the bourse in 2025, reflecting renewed investor confidence driven by sharply improved earnings.
Trading data shows that about 11.7 million shares of the pharmaceutical manufacturer have exchanged hands during the period, underscoring strong bullish momentum and heightened market participation. Analysts attribute the surge largely to the company’s robust nine-month financial performance, marked by explosive revenue growth and a significant expansion in profitability.
Earnings momentum fuels investor confidence
The rally follows the release of Mecure Industries’ unaudited financial results for the nine months ended September 2025, which revealed a 186 percent jump in profit before tax to ₦6.37 billion, compared with ₦2.23 billion recorded in the corresponding period of 2024. The sharp rise in earnings was underpinned by booming sales across the company’s core product lines, reflecting stronger market penetration and increased demand for pharmaceutical products.
Revenue for the period nearly doubled, rising 98.6 percent year-on-year to ₦60.01 billion. Segmental analysis highlights broad-based growth across the company’s portfolio. Acute medications generated ₦33.64 billion in revenue, almost double the prior year’s figure, while over-the-counter (OTC) products rose to ₦11.38 billion from ₦5.73 billion. Supplements contributed ₦8.50 billion, chronic medications delivered ₦5.43 billion, and narcotics accounted for ₦1.05 billion, all posting solid gains.
Cost pressures contained, margins improve
Despite operating in a high-cost environment, Mecure Industries managed to preserve and slightly improve margins. Cost of sales increased by 96 percent, broadly in line with revenue growth, driven by higher raw material prices and increased depreciation linked to capacity expansion, including investments in a new corticosteroid manufacturing facility.
Even so, gross profit margin edged up to 34 percent from 33.2 percent in the prior year, signalling improved operational efficiency. Operating expenses rose by 50 percent, reflecting higher marketing spend, administrative overheads, utilities, and logistics costs as the company scaled up operations.
Notwithstanding these pressures, operating profit climbed to ₦13 billion, lifting the operating margin to 21.7 percent from 16.6 percent a year earlier. The margin expansion suggests that revenue growth is increasingly outpacing cost increases, a trend investors appear to be rewarding.
Balance sheet expansion and rising leverage
On the balance sheet, total assets grew significantly to ₦78.23 billion, up from ₦54.84 billion at the end of 2024, reflecting expansion investments and higher working capital requirements. However, the growth came alongside increased leverage.
Total borrowings rose 49 percent to ₦53.71 billion, driven mainly by commercial paper issuances of ₦28.73 billion and working capital loans amounting to ₦10.43 billion. The higher debt load has contributed to increased finance costs, which remains a key risk factor investors are monitoring.
Nevertheless, market participants appear willing to look past the rising finance costs, focusing instead on the company’s strong earnings trajectory and revenue momentum.
Stock price journey in 2025
Mecure Industries’ share price performance in 2025 has been anything but linear. The stock opened the year at ₦13.90 before sliding to ₦11.25 by March, representing a 19.06 percent decline in the first quarter amid weak sentiment across the broader equities market.
A modest recovery in the second quarter pushed the stock to ₦12.85, but the real breakout began in the third quarter. By September, the share price had surged to ₦26.10 as investors started to price in improving fundamentals. A brief pullback in November saw the stock dip 9.77 percent to ₦27.70, a level that proved to be a strong accumulation zone.
Investors capitalised on the dip, triggering a sharp rally in December that propelled the stock past ₦50 to its current level of ₦55.00. Year-to-date, Mecure Industries shares are up an extraordinary 295.68 percent on the NGX.
What investors should know
Mecure Industries Plc is a Nigerian pharmaceutical and nutraceutical manufacturer producing generic and specialty drugs, including tablets, capsules, syrups, multivitamins, and dietary supplements. Incorporated in 2005 and headquartered in Lagos, the company has steadily expanded its production capacity and product offerings.
If current earnings momentum and investor interest are sustained, 2025 could mark the company’s strongest year yet on the Nigerian Exchange, positioning Mecure Industries as a standout growth stock in Nigeria’s healthcare sector.
Emmanuel Bassey is a Financial Expert that has worked in the Banking and Finance Industry for over 15+ years across different banks in Nigeria
